Q-omics provides the consensus-scored LAYN profile across patient tissues and cancer cell-line models. LAYN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LAYN is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LAYN RNA expression shows 21,078 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where LAYN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAYN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAYN survival associations across molecular data types. LAYN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAYN RNA expression–survival associations across cancer types. High LAYN expression shows unfavorable associations in UVM, MESO, OV and BLCA, but favorable associations in CHOL and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LAYN RNA expression.
This table summarizes LAYN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for LAYN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAYN shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher LAYN RNA expression in tumor versus normal tissue (log2 FC = +1.420, t-test p < 0.001).
This table shows molecular features associated with LAYN in patient tissues and cancer cell lines. In patient samples, LAYN shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAYN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
